Adial Pharmaceuticals Inc (ADIL) FinancialsADILAdial Pharmaceuticals Inc

In the context of the broader market, ADIL competes directly with industry leaders such as DARE and LSTA. With a market capitalization of $16.43M, it holds a leading position in the sector. When comparing efficiency, ADIL's gross margin of N/A stands against DARE's -70.57% and LSTA's N/A. Such benchmarking helps identify whether Adial Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Adial Pharmaceuticals has shown a significant improvement in its financial outlook with the acquisition of Azora Therapeutics, which is expected to enhance its pipeline for treating serious inflammatory diseases. The company has a current ratio of 5.63, indicating strong liquidity, but it has also reported negative net income figures, with -2,022,392 USD in Q1 2026.